SCHEDULE 7STANDARD PROVISIONS FOR MANUFACTURING AUTHORISATIONS

PART 1INTERPRETATION

F1In this Schedule—

F3 “Commission Directive 2003/94/EC” in relation to the holder of an authorisation means—

a

in the case of a holder in Great Britain—

i

Commission Directive 2003/94/EC laying down the principles and guidelines of good manufacturing practice for medicinal products for human use and for investigational medicinal products for human use, as modified by Schedule 2A to the 2012 Regulations, or

ii

if Regulations have been made under the powers in regulation B17(1) of the 2012 Regulations, and have come into force, those Regulations;

b

in the case of a holder in Northern Ireland, Commission Directive 2003/94/EC laying down the principles and guidelines of good manufacturing practice for medicinal products for human use and for investigational medicinal products for human use;

F4“product specification” means—

F2a

in the case of an investigational medicinal product manufactured before a request for authorisation to conduct the clinical trial involving those products has been made—

i

in the case of an investigational medicinal product manufactured or assembled in Great Britain, in accordance with regulation 17, or

ii

in the case of an investigational medicinal product manufactured or assembled in Northern Ireland, in accordance with regulation 17 or any equivalent provisions in any EEA State,

the specification for that product provided by the person who is to act as the sponsor of the proposed clinical trial,

b

in the case of an investigational medicinal product manufactured for the purpose of export, the specification for that product provided by the person to whose order the products are manufactured, or

c

in any other case, the specification for an investigational medicinal product contained in the investigational medicinal product dossier for that product.